GSK India appoints Mr Sridhar Venkatesh as Managing Director & VP

Mumbai: Mr Sridhar Venkatesh has been appointed as Managing Director & VP of GSK India effective 1 April 2020. He succeeds Mr Annaswamy Vaidheesh who will retire from the Company effective 31 March 2020.

Mr Venkatesh is a senior business leader with more than 24 years of diverse experience in pharmaceuticals & healthcare and has a strong track record of success in multiple roles within GSK. He joined GSK in 2011 as Head of Commercial, Established Products, Branded Generics, and moved as General Manager, Singapore before taking up the role of Commercial Head, India from 2014 to 2016. He was then promoted as VP of Central America & Caribbean before taking the current role as Vice President, Emerging Markets East with direct management of six markets (Philippines, Vietnam, Thailand, Malaysia, Indonesia, and Sri Lanka).

Mr Venkatesh is a Registered Pharmacist, with a Master's in Pharmacy (Pharmaceutical Marketing). Commenting on the appointment Mrs Renu Karnad, Chairperson of the Company said, "I warmly welcome Sridhar to lead GSK in our next phase of growth to serve the patients of India. I would also like to take this opportunity to thank Vaidheesh for his leadership during the last 5 years. Vaidheesh has represented the company with great skill and has helped GSK India become a positive force for change on many important matters. I am grateful for the excellent counsel and support he has provided to the Board. I wish him success in all his future endeavours."

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer.

Recently GlaxoSmithKline plc (GSK) and Innoviva, Inc. (INVA) has announced the acceptance of a regulatory submission seeking an additional indication for the use of once-daily, single-inhaler triple therapy, Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol or FF/UMEC/VI) for the treatment of asthma in adults by the European Medicines Agency (EMA).

Read also: EMA accepts GSK filing for Trelegy Ellipta use in adults with asthma